SLC5A2 and Myocardial fibrosis: Recent electrophysiological and translational studies further expand the pleiotropic profile of SGLT2 inhibitors, suggesting potential favorable effects on arrhythmic substrate, myocardial fibrosis, and electrical stability, reinforcing their multidimensional cardiovascular impact [37,38].